Aristides Capital LLC bought a new position in Option Care Health, Inc. (NASDAQ:OPCH – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 8,683 shares of the company’s stock, valued at approximately $241,000.
Several other hedge funds also recently made changes to their positions in OPCH. Algert Global LLC grew its holdings in Option Care Health by 12.4% in the 2nd quarter. Algert Global LLC now owns 197,797 shares of the company’s stock worth $5,479,000 after acquiring an additional 21,853 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in shares of Option Care Health by 7.2% during the second quarter. Mackenzie Financial Corp now owns 45,782 shares of the company’s stock worth $1,268,000 after purchasing an additional 3,070 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Option Care Health by 16.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,759,061 shares of the company’s stock valued at $48,726,000 after purchasing an additional 244,876 shares during the period. Dark Forest Capital Management LP bought a new position in Option Care Health during the 2nd quarter valued at approximately $210,000. Finally, Deerfield Management Company L.P. Series C purchased a new stake in Option Care Health in the 2nd quarter worth approximately $300,000. 98.05% of the stock is owned by hedge funds and other institutional investors.
Option Care Health Trading Down 0.4 %
OPCH opened at $31.30 on Tuesday. The company has a quick ratio of 1.36, a current ratio of 1.76 and a debt-to-equity ratio of 0.78. Option Care Health, Inc. has a 52 week low of $26.11 and a 52 week high of $34.63. The stock has a market cap of $5.44 billion, a PE ratio of 20.59, a PEG ratio of 2.42 and a beta of 1.29. The business has a 50 day moving average of $31.29 and a 200-day moving average of $30.40.
Insider Activity
In related news, CFO Michael H. Shapiro sold 23,217 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $30.95, for a total value of $718,566.15. Following the transaction, the chief financial officer now directly owns 247,317 shares of the company’s stock, valued at approximately $7,654,461.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Elizabeth Quadros Betten sold 47,531 shares of Option Care Health stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $31.09, for a total value of $1,477,738.79. Following the completion of the sale, the director now directly owns 21,339 shares in the company, valued at approximately $663,429.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Michael H. Shapiro sold 23,217 shares of the company’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $30.95, for a total transaction of $718,566.15. Following the transaction, the chief financial officer now owns 247,317 shares in the company, valued at approximately $7,654,461.15. The disclosure for this sale can be found here. Corporate insiders own 0.64% of the company’s stock.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on the company. JMP Securities boosted their target price on Option Care Health from $36.00 to $37.00 and gave the company a “market outperform” rating in a research note on Monday. Barrington Research boosted their price objective on shares of Option Care Health from $38.00 to $40.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st.
Option Care Health Company Profile
Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.
Recommended Stories
- Five stocks we like better than Option Care Health
- What is the Australian Securities Exchange (ASX)
- Instacart Is Revolutionizing Groceries: Why It’s Time to Invest
- How to Calculate Retirement Income: MarketBeat’s Calculator
- DraftKings Is the Real MVP of the 2025 NFL Football Season
- ESG Stocks, What Investors Should Know
- TJX Stock: A Buying Opportunity Before the Holiday Rush
Receive News & Ratings for Option Care Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Option Care Health and related companies with MarketBeat.com's FREE daily email newsletter.